Second Sight Medical Products (NASDAQ:EYES) released its earnings results on Tuesday. The medical device company reported ($0.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.01), Bloomberg Earnings reports. The firm had revenue of $1.28 million during the quarter, compared to analyst estimates of $0.45 million. Second Sight Medical Products had a negative net margin of 497.18% and a negative return on equity of 326.46%.
Shares of NASDAQ EYES traded up $0.01 during midday trading on Wednesday, hitting $0.79. The stock had a trading volume of 180,100 shares, compared to its average volume of 289,239. The stock has a 50-day simple moving average of $0.81. The stock has a market cap of $94.67 million, a price-to-earnings ratio of -1.52 and a beta of 2.27. Second Sight Medical Products has a fifty-two week low of $0.63 and a fifty-two week high of $1.98. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.50 and a current ratio of 4.71.
A hedge fund recently bought a new stake in Second Sight Medical Products stock. Wiley BROS. Aintree Capital LLC acquired a new position in shares of Second Sight Medical Products Inc (NASDAQ:EYES) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 51,961 shares of the medical device company’s stock, valued at approximately $41,000. Institutional investors own 6.09% of the company’s stock.
EYES has been the subject of several research reports. Zacks Investment Research raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Monday, June 17th. ValuEngine cut Second Sight Medical Products from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th.
About Second Sight Medical Products
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
Featured Article: How a Put Option Works
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.